Risk factors of multi-drug resistant organism infection after liver transplantation: a single-center clinical trial
-
摘要:
目的 分析肝移植术后发生多重耐药菌(MDRO)感染的危险因素。 方法 回顾性分析77例肝移植受者的临床资料,根据是否发生MDRO感染分为非MDRO感染组(51例)及MDRO感染组(26例)。总结肝移植受者术后MDRO的感染率和菌株分布情况;分析肝移植受者术后发生MDRO感染的危险因素;比较两组受者的预后情况。 结果 肝移植术后MDRO感染率为34%(26/77),主要为耐碳青霉烯类MDRO感染,主要感染部位为肺部、腹腔和切口。单因素分析提示术后气管插管≥48 h、重症监护室(ICU)入住时间≥72 h、住院时间≥30 d、再次手术、持续性肾脏替代治疗(CRRT)和他克莫司(Tac)血药浓度≥15 ng/mL是肝移植术后发生MDRO感染的危险因素。Cox回归分析提示术后气管插管≥48 h、再次手术、CRRT和Tac血药浓度≥15 ng/mL是肝移植术后发生MDRO感染的独立危险因素。MDRO感染组病死率高于非MDRO感染组[31%(8/26)比10%(5/51),P=0.01]。 结论 术后气管插管≥48 h、再次手术、CRRT和Tac血药浓度≥15 ng/mL会增加肝移植术后MDRO感染的风险,影响受者的预后。 Abstract:Objective To analyze the risk factors of multi-drug resistant organism (MDRO) infection after liver transplantation. Methods The clinical data of 77 recipients undergoing liver transplantation were retrospectively analyzed. According to the incidence of MDRO infection, all recipients were divided into the non-MDRO infection group (n=51) and MDRO infection group (n=26). The infection rate and strain distribution of MDRO in liver transplant recipients were summarized. The risk factors of MDRO infection in liver transplant recipients were identified. Clinical prognosis of all recipients was statistically compared between two groups. Results The infection rate of MDRO after liver transplantation was 34% (26/77), mainly carbapenem-resistant MDRO infection. The main sites of infection included lung, abdominal cavity and incision. Univariate analysis showed that postoperative tracheal intubation ≥48 h, length of intensive care unit (ICU) stay ≥72 h, length of hospital stay ≥30 d, re-operation, continuous renal replacement therapy (CRRT) and tacrolimus (Tac) blood concentration ≥15 ng/mL were the risk factors for MDRO infection after liver transplantation. Cox regression analysis indicated that postoperative tracheal intubation≥48 h, re-operation, CRRT and Tac blood concentration ≥15 ng/mL were the independent risk factors for MDRO infection after liver transplantation. The fatality in the MDRO infection group was significantly higher than that in the non-MDRO infection group [31%(8/26) vs. 10%(5/51), P=0.01]. Conclusions Postoperative tracheal intubation ≥48 h, re-operation, CRRT and Tac blood concentration ≥15 ng/mL may increase the risk of MDRO infection after liver transplantation and affect clinical prognosis of the recipients. -
表 1 肝移植术后发生MDRO感染危险因素的单因素分析
Table 1. Univariate analysis of risk factors for MDRO infection after liver transplantation [n(%)]
变量 非MDRO感染组(n=51) MDRO感染组(n=26) χ2值 P值 术前指标 年龄≥55岁 13(25) 4(15) 0.198 0.657 性别 0.127 0.722 男 40(78) 21(81) 女 11(22) 5(19) 原发病 乙肝肝硬化失代偿 26(51) 10(38) 1.084 0.298 肝细胞癌 10(20) 4(15) 0.020 0.887 终末期良性胆道病 9(18) 5(19) < 0.001 1.000 其他 6(12) 7(27) 1.843 0.175 MELD/PELD评分≥25分 15(29) 9(35) 0.983 0.322 Child-Pugh C级 27(53) 18(69) 0.316 0.574 住院时间≥30 d 7(14) 9(35) 1.073 0.300 合并感染 5(10) 6(23) 2.121 0.145 供者来源性感染 8(16) 5(19) 3.054 0.081 术中指标 手术时间≥8 h 22(43) 11(42) 0.062 0.803 无肝期≥60 min 30(59) 11(42) 3.357 0.067 失血量≥2 L 14(27) 9(35) 0.002 0.961 输血量≥8 U 20(39) 12(46) 0.009 0.923 术后指标 气管插管≥48 h 9(18) 15(58) 15.831 < 0.001 ICU入住时间≥72 h 15(29) 16(62) 4.618 0.032 住院时间≥30 d 13(25) 18(69) 5.228 0.022 再次手术 1(2) 6(23) 9.505 0.002 CRRT 4(8) 7(27) 11.868 0.001 胆道并发症 4(8) 5(19) 0.738 0.390 Tac血药浓度≥15 ng/ mL 7(14) 9(35) 5.911 0.015 血红蛋白≥60 g/L 4(8) 5(19) 1.029 0.310 白蛋白≥35 g/L 15(29) 10(38) 1.328 0.249 表 2 肝移植术后发生MDRO感染危险因素的Cox回归分析
Table 2. Cox regression analysis of risk factors for MDRO infection after liver transplantation
变量 β值 SE① OR② 95%CI③ P值 气管插管≥48 h 0.956 0.460 2.601 1.055~6.413 0.038 再次手术 1.666 0.523 5.292 1.898~14.759 0.001 CRRT 1.453 0.556 4.276 1.438~12.716 0.009 Tac血药浓度≥15 ng/mL 1.459 0.473 4.302 1.701~10.882 0.002 注:①SE为标准误。
②OR为比值比。
③CI为可信区间。 -
[1] STARZL TE. The long reach of liver transplantation[J]. Nat Med, 2012, 18(10): 1489-1492. DOI: 10.1038/nm.2927. [2] 郑树森, 俞军, 张武. 肝移植在中国的发展现状[J]. 临床肝胆病杂志, 2014, 30(1): 2-4. DOI: 10.3969/j.issn. 1001-5256.2014.01.001.ZHENG SS, YU J, ZHANG W. Current development of liver transplantation in China[J]. J Clin Hepatol, 2014, 30(1): 2-4. DOI: 10.3969/j.issn.1001-5256.2014.01.001. [3] SHAFIEKHANI M, MIRJALILI M, VAZIN A. Prevalence, risk factors and treatment of the most common Gram-negative bacterial infections in liver transplant recipients: a review[J]. Infect Drug Resist, 2019, 12: 3485-3495. DOI: 10.2147/IDR.S226217. [4] 林栋栋, 刘晋宁. 肝移植围术期感染的处理[J]. 北京医学, 2017, 39(9): 895-896. DOI: 10.15932/j.0253-9713. 2017.09.001.LIN DD, LIU JN. Management of perioperative infection in liver transplantation[J]. Beijing Med J, 2017, 39(9): 895-896. DOI: 10.15932/j.0253-9713.2017.09.001. [5] IDOSSA DW, SIMONETTO DA. Infectious complications and malignancies arising after liver transplantation[J]. Anesthesiol Clin, 2017, 35(3): 381-393. DOI: 10.1016/j.anclin.2017.04.002. [6] SANTORO-LOPES G, DE GOUVÊA EF. Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge[J]. World J Gastroenterol, 2014, 20(20): 6201-6210. DOI: 10.3748/wjg.v20.i20.6201. [7] KALPOE JS, SONNENBERG E, FACTOR SH, et al. Mortality associated with carbapenem-resistant klebsiella pneumoniae infections in liver transplant recipients[J]. Liver Transpl, 2012, 18(4): 468-474. DOI: 10.1002/lt.23374. [8] AGUADO JM, SILVA JT, FERNÁNDEZ-RUIZ M, et al. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations[J]. Transplant Rev (Orlando), 2018, 32(1): 36-57. DOI: 10.1016/j.trre.2017.07.001. [9] TU Z, XIANG P, XU X, et al. DCD liver transplant infection: experience from a single centre in China[J]. Int J Clin Pract, 2016, 70(Suppl 185): 3-10. DOI10.1111/ijcp.12810. doi: 10.1111/ijcp.12810 [10] 姚兴伟, 林英, 杨琦, 等. 248株碳青霉烯类耐药肠杆菌科细菌临床特点及耐药性分析[J]. 中国实验诊断学, 2020, 24(2): 320-322.YAO XW, LIN Y, YANG Q, et al. Analysis on clinical characteristics and drug resistance in 248 strains of carbapenems-resistant enterobacteriaceae bacteria[J]. Chin J Lab Diagn, 2020, 24(2): 320-322. [11] OLSON JC, KARVELLAS CJ. Critical care management of the patient with cirrhosis awaiting liver transplant in the intensive care unit[J]. Liver Transpl, 2017, 23(11): 1465-1476. DOI: 10.1002/lt.24815. [12] GHANSHANI R, GUPTA R, GUPTA BS, et al. Epidemiological study of prevalence, determinants, and outcomes of infections in medical ICU at a tertiary care hospital in India[J]. Lung India, 2015, 32(5): 441-448. DOI: 10.4103/0970-2113.164155. [13] LEWIS JD, BARROS AJ, SIFRI CD. Comparison of risk factors and outcomes of daptomycin-susceptible and -nonsusceptible vancomycin-resistant enterococcus faecium infections in liver transplant recipients[J]. Transpl Infect Dis, 2018, 20(3): e12856. DOI: 10.1111/tid.12856. [14] TAKEDA K, TANAKA K, KUMAMOTO T, et al. Emergency versus elective living-donor liver transplantation: a comparison of a single center analysis[J]. Surg Today, 2012, 42(5): 453-459. DOI: 10.1007/s00595-011-0040-5. [15] 浦燕萍, 顾燕, 杨富, 等. 肝移植患者术后多重耐药鲍曼不动杆菌感染影响因素[J/CD]. 中华肝脏外科手术学电子杂志, 2016, 5(3): 158-162. DOI: 10.3877/cma.j.issn.2095-3232.2016.03.008.PU YP, GU Y, YANG F, et al. Influencing factors of multi-drug resistant acinetobacter baumannii infection in patients after liver transplantation[J/CD]. Chin J Hepatic Surg (Electr Edit), 2016, 5(3): 158-162. DOI: 10.3877/cma.j.issn.2095-3232.2016.03.008. [16] JAGARLAMUDI N, WONG F. Acute kidney injury: prediction, prognostication and optimisation for liver transplant[J]. Hepatol Int, 2020, 14(2): 167-179. DOI: 10.1007/s12072-020-10018-0. [17] DOUCETTE KE, AL-SAIF M, KNETEMAN N, et al. Donor-derived bacteremia in liver transplant recipients despite antibiotic prophylaxis[J]. Am J Transplant, 2013, 13(4): 1080-1083. DOI: 10.1111/ajt.12133. [18] 姚运海, 甘建和, 赵卫峰. 4种评分系统对肝硬化合并感染患者预后的评估价值[J]. 临床肝胆病杂志, 2019, 35(1): 87-91. DOI: 10.3969/j.issn.1001-5256.2019.01.016.YAO YH, GAN JH, ZHAO WF. Value of four scoring systems in evaluating the prognosis of cirrhotic patients with infection[J]. J Clin Hepatol, 2019, 35(1): 87-91. DOI: 10.3969/j.issn.1001-5256.2019.01.016. [19] 陆晔峰, 夏强, 邱必军, 等. 儿童肝移植术后长期生存的相关问题分析[J]. 临床肝胆病杂志, 2019, 35(11): 2396-2401. DOI: 10.3969/j.issn.1001-5256.2019.11.004.LU YF, XIA Q, QIU BJ, et al. An analysis of related issues in long-term survival in children after liver transplantation[J]. J Clin Hepatol, 2019, 35(11): 2396-2401. DOI: 10.3969/j.issn.1001-5256.2019.11.004. [20] FREIRE MP, OSHIRO IC, PIERROTTI LC, et al. Carbapenem-resistant enterobacteriaceae acquired before liver transplantation: impact on recipient outcomes[J]. Transplantation, 2017, 101(4): 811-820. DOI: 10.1097/TP.0000000000001620. [21] CINAR G, KALKAN İA, AZAP A, et al. Carbapenemase-producing bacterial infections in patients with liver transplant[J]. Transplant Proc, 2019, 51(7): 2461-2465. DOI: 10.1016/j.transproceed.2019.02.050. [22] FURUICHI M, FUKUDA A, SAKAMOTO S, et al. Characteristics and risk factors of late-onset bloodstream infection beyond 6 months after liver transplantation in children[J]. Pediatr Infect Dis J, 2018, 37(3): 263-268. DOI: 10.1097/INF.0000000000001754. [23] SHI SH, KONG HS, JIA CK, et al. Risk factors for pneumonia caused by multidrug-resistant Gram-negative bacilli among liver recipients[J]. Clin Transplant, 2010, 24(6): 758-765. DOI: 10.1111/j.1399-0012.2009.01184.x. [24] JUNG JY, PARK MS, KIM SE, et al. Risk factors for multi-drug resistant acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit[J]. BMC Infect Dis, 2010, 10: 228. DOI: 10.1186/1471-2334-10-228. [25] KIM YJ, KIM SI, LEE YD, et al. Carbapenem-resistant acinetobacter baumannii bacteremia in liver transplant recipients[J]. Transplant Proc, 2018, 50(4): 1132-1135. DOI: 10.1016/j.transproceed.2018.01.043. [26] AVKAN-OGUZ V, OZKARDESLER S, UNEK T, et al. Risk factors for early bacterial infections in liver transplantation[J]. Transplant Proc, 2013, 45(3): 993-997. DOI: 10.1016/j.transproceed.2013.02.067. [27] NATORI Y, KASSAR R, IABONI A, et al. Surgical site infections after liver transplantation: prospective surveillance and evaluation of 250 transplant recipients in Canada[J]. Infect Control Hosp Epidemiol, 2017, 38(9): 1084-1090. DOI: 10.1017/ice.2017.131. [28] VIEHMAN JA, CLANCY CJ, CLARKE L, et al. Surgical site infections after liver transplantation: emergence of multidrug-resistant bacteria and implications for prophylaxis and treatment strategies[J]. Transplantation, 2016, 100(10): 2107-2114. DOI: 10.1097/TP.0000000000001356.